Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing

Background: A fixed dose of 200 mg of pembrolizumab every 3 weeks (Q3W) is the standard of care for patients with stage IV non-small cell lung cancer (NSCLC) and PDL1 ≥50%. In April 2020, based on pharmacokinetic modeling without formal comparative studies, the FDA approved 400 mg every 6 weeks (Q6W...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Lauren, Rittberg, Rebekah, Leung, Bonnie, Shokoohi, Aria, Pender, Alexandra, Wong, Selina, Al-Hashami, Zamzam, Wang, Ying, Ho, Cheryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689400/
https://www.ncbi.nlm.nih.gov/pubmed/36421338
http://dx.doi.org/10.3390/curroncol29110685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689400/
https://www.ncbi.nlm.nih.gov/pubmed/36421338
http://dx.doi.org/10.3390/curroncol29110685

Ejemplares similares